Abstract: A method with which uranium from a natural uranium concentrate may be purified, including a) extracting the uranium present as uranyl nitrate in an aqueous phase A1 resulting from the dissolution of the natural uranium concentrate in nitric acid, by means of an organic phase which contains an extractant in an organic diluent; b) washing the organic phase obtained at the end of step a), with an aqueous phase A2; and c) stripping the uranyl nitrate of the organic phase obtained at the end of step b), by circulating this organic phase in an apparatus, as a counter current against an aqueous phase A3. The extractant is an N,N-dialkylamide and the ratio between the flow rate at which the organic phase obtained at the end of step b) and the aqueous phase A3 circulate in the apparatus where step c) occurs, is greater than 1.

Abstract: A method with which uranium from a natural uranium concentrate may be purified, including a) extracting the uranium present as uranyl nitrate in an aqueous phase A1 resulting from the dissolution of the natural uranium concentrate in nitric acid, by means of an organic phase which contains an extractant in an organic diluent; b) washing the organic phase obtained at the end of step a), with an aqueous phase A2; and c) stripping the uranyl nitrate of the organic phase obtained at the end of step b), by circulating this organic phase in an apparatus, as a counter current against an aqueous phase A3. The extractant is an N,N-dialkylamide and the ratio between the flow rate at which the organic phase obtained at the end of step b) and the aqueous phase A3 circulate in the apparatus where step c) occurs, is greater than 1.

Abstract: The appliance comprises an IC card reader for an operation with an IC card and a power supply for providing a supply voltage, in particular for the IC card. The appliance comprises further an overload protection circuit, which simulates an IC card extraction in case of an overload of the supply voltage. The power supply is then immediately switched off to avoid any damage for the power supply. In a preferred embodiment, the IC card reader is equipped with a card presence switch for indicating to a micro-controller of the appliance, that an IC card has been inserted into the card reader. The micro-controller provides then a control signal for switching on the power supply for the operation with the IC card. The protection circuit is coupled between the supply voltage for the IC card and the signal line of the card presence switch and provides a detection of a short circuit. The protection circuit may comprise a diode, a comparator or a transistor, which switches off the power supply via a logic circuit.

Abstract: A compound, in the form of a pure optical isomer or a mixture thereof, of formula (I): ##STR1## in which: Z represents a group of formula --CH.sub.2 --, --C(CH.sub.3).sub.2 --, --CH.dbd.CH--, --(CH.sub.2).sub.2 --, --(CH.sub.2).sub.3 --, --NH-- or --N(CH.sub.3)CH.sub.2 --, in which the nitrogen is bonded to the carbonyl group;R1 represents hydrogen or a C.sub.1 -C.sub.4 alkyl group;R2 represents hydrogen or a methyl group; andR3 represents:a phenoxy group which is unsubstituted or substituted by a halogen or a methyl group,a naphthyloxy group,a phenylmethyl group substituted by a halogen or a methyl group,an unsubstituted phenylmethyl group when Z does not representa group of formula --CH.dbd.CH-- or --(CH.sub.2).sub.

Abstract: Ifenprodil and its analogues are useful for the treatment of psychoses such as schizophrenia.

Abstract: Compounds of the formula: ##STR1## wherein R.sub.1 is hydrogen, halogen, trifluoromethyl, alkyl, hydroxyl, alkyoxy, benzyloxy, alkanoyloxy, or benzoyloxy, or when R.sub.2 is hydroxyl or methoxy in the 4-position and R.sub.3 is hydrogen, R.sub.1 may also represent hydroxymethyl carbamoyl or alkoxycarbonyl,R.sub.2 is hydrogen, halogen, alkyl, hydroxyl, or alkoxy,R.sub.3 is hydrogen or alkyl,R.sub.4 is alkyl (in which case the compounds are (.+-.)-erythro) or when R.sub.3 represents hydrogen, R.sub.4 may also be hydrogen, and R.sub.5 is hydrogen, halogen, alkyl, alkoxy, or three methoxy groups in the 3-, 4- and 5-positions and pharmaceutically acceptable acid addition salts thereof, with the exclusion of compounds wherein:(a) one of R.sub.1 and R.sub.2 is in the 4-position and is hydroxyl, alkoxy or benzyloxy, the other is in the 3-position and is hydrogen, hydroxyl, alkoxy or benzyloxy, and R.sub.3 and R.sub.5 are hydrogen and wherein:(b) R.sub.1 is in the 4-position and is halogen, R.sub.4 is methyl and R.sub.

Abstract: Compounds of general formula (I) ##STR1## wherein R1 represents a phenyl, halophenyl, methylphenyl, ethylphenyl, methoxyphenyl, trifluoromethylphenyl or naphthyl group, R2 represents hydrogen or a methyl or phenyl group, and R3 represents hydrogen or a benzyl group, except compounds in which R1 is a phenyl or 4-fluorophenyl group, R2 is hydrogen and R3 is hydrogen or a benzyl group, and their pharmaceutically acceptable acid addition salts have useful anti-depressant and anti-ischaemic properties.

Abstract: Compounds of the formula: ##STR1## wherein R.sub.1 represents hydrogen, chlorine or methoxy, R.sub.2 represents hydrogen, methyl or benzyl, and R.sub.3 and R.sub.4 represent hydrogen, or R.sub.3 represents methyl and R.sub.4 represents hydrogen or R.sub.3 represents hydrogen and R.sub.4 represents methyl, are new compounds useful in therapy as they possess an antianoxic activity.

Abstract: Compounds of the general formula: ##STR1## wherein R.sub.1 represents hydrogen, chlorine or methoxy, R.sub.2 represents hydrogen, methyl or benzyl, and R.sub.3 and R.sub.4 represent hydrogen, or R.sub.3 represents methyl and R.sub.4 represents hydrogen, or R.sub.3 represents hydrogen and R.sub.4 represents methyl, with the exception of those compounds wherein R.sub.1, R.sub.3 and R.sub.4 each represent a hydrogen atom simultaneously, are new therapeutically useful compounds; they possess an antianoxic activity.